Concepts (63)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytoreduction Surgical Procedures | 7 | 2024 | 92 | 1.680 |
Why?
|
| Peritoneal Neoplasms | 7 | 2024 | 184 | 1.220 |
Why?
|
| Hyperthermia, Induced | 6 | 2024 | 75 | 1.110 |
Why?
|
| Insurance | 1 | 2022 | 12 | 0.750 |
Why?
|
| Stomach Neoplasms | 1 | 2022 | 308 | 0.600 |
Why?
|
| Appendiceal Neoplasms | 3 | 2023 | 37 | 0.560 |
Why?
|
| Metaplasia | 1 | 2018 | 39 | 0.560 |
Why?
|
| Colorectal Neoplasms | 5 | 2024 | 1053 | 0.540 |
Why?
|
| Databases, Factual | 2 | 2018 | 1006 | 0.500 |
Why?
|
| Laparoscopy | 1 | 2022 | 782 | 0.470 |
Why?
|
| Breast Neoplasms | 3 | 2018 | 3110 | 0.470 |
Why?
|
| Patient Selection | 1 | 2017 | 690 | 0.400 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 1103 | 0.370 |
Why?
|
| Axilla | 3 | 2018 | 109 | 0.300 |
Why?
|
| Medical Oncology | 2 | 2023 | 404 | 0.290 |
Why?
|
| Survival Rate | 6 | 2023 | 1948 | 0.270 |
Why?
|
| Combined Modality Therapy | 5 | 2024 | 1723 | 0.260 |
Why?
|
| Lymph Node Excision | 2 | 2018 | 233 | 0.240 |
Why?
|
| Follow-Up Studies | 4 | 2022 | 3830 | 0.210 |
Why?
|
| Palliative Care | 2 | 2023 | 269 | 0.210 |
Why?
|
| Surgical Oncology | 1 | 2023 | 29 | 0.200 |
Why?
|
| Appendix | 1 | 2023 | 30 | 0.190 |
Why?
|
| Gastrectomy | 1 | 2022 | 71 | 0.180 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 76 | 0.180 |
Why?
|
| Patients | 1 | 2022 | 103 | 0.180 |
Why?
|
| Humans | 14 | 2024 | 93515 | 0.170 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2018 | 86 | 0.160 |
Why?
|
| Education, Medical, Graduate | 1 | 2023 | 425 | 0.150 |
Why?
|
| Aged | 4 | 2022 | 20434 | 0.140 |
Why?
|
| Curriculum | 1 | 2023 | 594 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 920 | 0.140 |
Why?
|
| Middle Aged | 5 | 2023 | 27573 | 0.140 |
Why?
|
| Carcinoma, Lobular | 1 | 2018 | 84 | 0.130 |
Why?
|
| Prognosis | 3 | 2023 | 3911 | 0.130 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2018 | 165 | 0.130 |
Why?
|
| Retrospective Studies | 5 | 2023 | 10164 | 0.120 |
Why?
|
| Mastectomy | 1 | 2018 | 262 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2023 | 1173 | 0.120 |
Why?
|
| Female | 5 | 2023 | 48702 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2023 | 1090 | 0.100 |
Why?
|
| Peritoneum | 2 | 2024 | 52 | 0.100 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 2 | 2023 | 18 | 0.100 |
Why?
|
| Surgeons | 1 | 2017 | 292 | 0.100 |
Why?
|
| Age Factors | 1 | 2017 | 1906 | 0.100 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 2017 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2022 | 2562 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 2544 | 0.070 |
Why?
|
| Adult | 4 | 2023 | 27918 | 0.070 |
Why?
|
| Advance Directives | 1 | 2023 | 64 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2023 | 40 | 0.050 |
Why?
|
| Male | 1 | 2022 | 44557 | 0.040 |
Why?
|
| Students, Medical | 1 | 2023 | 435 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2018 | 196 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2023 | 3054 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 572 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2018 | 413 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2018 | 280 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1780 | 0.030 |
Why?
|
| Mutation | 1 | 2023 | 4272 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 1660 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 7061 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 6930 | 0.010 |
Why?
|
| Adolescent | 1 | 2018 | 9606 | 0.010 |
Why?
|